Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. - Wikidata - wikimedia - TriplyDB

Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

http://www.wikidata.org/entity/Q33858325

about

Interactions between xenoestrogens and ketoconazole on hepatic CYP1A and CYP3A, in juvenile Atlantic cod (Gadus morhua)Prime Drug Interplay in Dental Practice Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan Evidence for a basal release of a cytochrome-related endothelium-derived hyperpolarizing factor in the radial artery in humans Sequence diversity and haplotype structure at the human CYP3A cluster Systemic bioavailability of fluticasone proprionate Characterization of the Effect of Drug-Drug Interaction on Protein Binding in Concurrent Administration of Sulfamethoxazol and Diclofenac Sodium Using Bovine Serum Albumin Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data.Classification of a large microarray data set: algorithm comparison and analysis of drug signatures.Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors.Summary of information on human CYP enzymes: human P450 metabolism data.Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone.Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir.Low-dose doxepin for the treatment of insomnia: emerging data.Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.The Mycobacterium tuberculosis cytochrome P450 system.Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam.Building a tiered approach to in vitro predictive toxicity screening: a focus on assays with in vivo relevance.Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.Interaction of common azole antifungals with P glycoprotein Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions.Assessment of iontophoretic and passive ungual penetration by laser scanning confocal microscopy.Human drug metabolism and the cytochromes P450: application and relevance of in vitro models.Ketoconazole-Associated Liver Injury in Drug-Drug Interaction Studies in Healthy Volunteers.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics.Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers.Update on terbinafine with a focus on dermatophytoses Human CYPs: in vivo and clinical aspects.Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection Itraconazole--perspectives for the management of invasive aspergillosis.Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality.Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use.Analysis of cytochrome P450 CYP119 ligand-dependent conformational dynamics by two-dimensional NMR and X-ray crystallography.Systemic antifungal therapy: new options, new challenges.Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know.Clarithromycin extended-release tablet: a review of its use in the management of respiratory tract infections.Safety and efficacy of tinea pedis and onychomycosis treatment in people with diabetes: a systematic review

P2860

Q24805219-8DE50129-576C-4E45-ABAC-2491651B8E22 Q26748474-6B34122E-B89C-44EB-A2B6-4E068B7604F0 Q26851546-D81E75DD-3210-484D-9025-C717C2B8B5A3 Q28193867-49E7F97C-6BCD-4E31-8B1C-AACCF8104F4D Q28284189-CD23CBC0-41C6-42E4-B8A3-158A6A1EECF7 Q28362578-B0EC7A1B-054E-49C8-930B-2FA51B55AEA3 Q28468550-18572114-BCBC-4C83-97A8-D905F2A7444F Q30938859-B25DADFF-6C91-41AA-8D55-24620CDAC4BF Q30988746-5317F733-598D-4745-9483-7B180F04AACA Q32064655-B67B5F05-D9FA-44B4-9E97-2F7086FC6135 Q32103802-B51E2A72-B24E-492C-8D23-F92F10548670 Q33148910-E1DB40F0-F37D-4879-922A-3EB43067BA10 Q33186873-40870D74-D701-4496-A321-F8A3CD6EC60B Q33460649-7DC33DC2-E8C4-4D45-8AB7-AA7AE4CA7ADB Q33557148-33C94785-43E9-40D8-A33F-F074809B7970 Q33615471-15DA2EB8-1C74-4F84-AEDD-0EE348CD41DC Q33668215-7F8D0832-6C98-4B60-B256-E0D7FC106347 Q34015408-97B9B3E3-BF7C-4914-9D8B-323F894D50AB Q34019354-5161F60A-2B22-40B1-9DC9-944E20C88975 Q34104641-EA323F80-2BBF-4FB2-876C-318854E17901 Q34111158-732962FA-70D4-4366-B5CE-9B2BE8B9F56D Q34233142-5AC6ED07-FB8E-4CF5-B580-AA46306F8087 Q34368221-243B36E6-2879-4084-BB84-0CC755044A87 Q34430456-A474D2A8-BF9C-4BE3-B495-3129410308F8 Q34511634-3D6E13E4-99F3-444C-8D18-BF21F37EB71E Q34532546-B1B3A420-045A-421D-94D3-E292D0F6568B Q34563883-3F0DD61A-3750-492F-8FAC-9E041031CD8F Q34568883-09ADDDC0-E543-4ABE-A7B7-206B7699E6C1 Q34569361-50CA9BAF-190C-4853-87C4-E2AEA93E0C21 Q34620230-C0A8489D-119E-481F-8F6E-088A34E0ADC3 Q34627903-44EC4C60-1FDA-48D3-92C2-44766AD3C301 Q34976284-96647651-F2B8-43C8-BE2D-41562346606A Q35105394-A74569A9-66B2-4003-80A2-3AC9FFAB5655 Q35166739-4993986E-5309-4AE7-BE94-2417285671C3 Q35364006-D7D26CE4-D73E-4735-A202-68F14468FAEF Q35450924-0CE409C4-BE67-481D-AA88-776197017B1D Q35585219-1AB4F005-686D-4EB1-BFD7-BFDBFD293EC1 Q35608207-64E9F97C-BCD0-4CB5-9D09-80E120CF97F1 Q35627730-BD0EDCAE-FF90-47B2-92C6-7512998113C9 Q35640828-6E6EB27E-8DD0-403E-BB05-479A7313B6F2

P2860

Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

http://www.wikidata.org/entity/Q33858325

description

2000 nî lūn-bûn

@nan

2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

@ast

Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

@en

type

label

Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

@ast

Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

@en

prefLabel

Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

@ast

Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

@en

P1433

Q33858325-7850B41C-5F90-4075-9F1A-1C83389DE183

P1476

Q33858325-B70D6506-1203-4B71-8C4C-12D32EE7C6FE

P2093

Q33858325-4C33605D-52CD-4DDE-86A3-00ED2C69F27A

Q33858325-B703AFD3-E5CA-428D-9491-9938E0424B1F

Q33858325-D23BEA55-3A99-4F98-9D65-265EC24B4EA3

P2860

Q33858325-0050324E-FBF0-49DC-8514-5F9798D7D728

Q33858325-01373446-43B1-4B11-9912-D0E296D37B08

Q33858325-14EA30C2-FF63-4275-9433-3411944746C0

Q33858325-2D40203F-AF84-4F0D-AA05-DE1AE96FDEEC

Q33858325-2F57DBB1-11D3-44A3-B3E8-C3FF9C7C81BF

Q33858325-44D80A7B-E769-4260-AF9C-302B5BF4A0FE

Q33858325-50EAD60E-233D-44F7-9E91-1E71561733FA

Q33858325-534A5524-A620-4629-A1F8-B977B601EE27

Q33858325-54194914-BD6F-4CC1-A323-A2F6903803A3

Q33858325-5496AD7B-6C5E-4A34-A00C-1E985C4976FC

P2888

Q33858325-2EC047AA-518E-4171-9FED-CEE632884084

P304

Q33858325-975077F2-00F1-4733-A68C-3F5E07264BF2

P31

Q33858325-52D1F6C4-0095-4600-B9FF-F83246E2EFCD

P356

Q33858325-54711038-8635-494B-B96F-822E688563F3

P433

Q33858325-61D582AE-E732-4C19-974A-71EE7BEC8DC1

P478

Q33858325-743FAB04-46CB-48DC-93FA-034A4F37C605

P577

Q33858325-03C531C8-CD33-4B47-AC2F-A25FFFA141A2

P6179

Q33858325-85452F78-EDFF-4B3E-A5A8-261FC76CDBBA

P698

Q33858325-81EFF27F-4C4F-4CA8-B16F-03655F493CFB

P356

00003088-200038020-00002

P1433

Clinical Pharmacokinetics

P1476

Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

@en

P2093

Greenblatt DJ

http://www.w3.org/2001/XMLSchema#string

Venkatakrishnan K

http://www.w3.org/2001/XMLSchema#string

von Moltke LL

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetics and metabolism of temazepam in man and several animal species

Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man

Cyclosporine and itraconazole interaction in heart and lung transplant recipients

Human liver microsomal metabolism of paclitaxel and drug interactions

Metabolism of theophylline by cDNA-expressed human cytochromes P-450.

Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2.

Disposition of ketoconazole, an oral antifungal, in humans

Effect of fluconazole on pharmacokinetics of 2',3'-dideoxyinosine in persons seropositive for human immunodeficiency virus.

Pharmacokinetics and bioavailability of fluconazole in two groups of males with human immunodeficiency virus (HIV) infection compared with those in a group of males without HIV infection

Induction potential of fluconazole toward drug-metabolizing enzymes in rats.

P2888

00003088-200038020-00002

P304

111-180

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/00003088-200038020-00002

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P577

2000-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1029425757

http://www.w3.org/2001/XMLSchema#string

P698

10709776

http://www.w3.org/2001/XMLSchema#string